Title: Yonhap News– DreamPharma developing new drug for super bacteria with LegoChem.

Publication: Yonhap News

Date: 28 December 2011

Summary

• DreamPharma signed a contract with LegoChem Bioscience for exclusive development and sales of Oxazolidinone antibiotics (LCB01-0371), drug for Methicillin-Resistant Staphylococcus Aureus (MRSA) and Vancomycin-Resistant Enterococcus (VRE)

• The super antibiotics demonstrated its superior efficacy on MRSA and VRE to Pfizer’s Zyvox through preclinical study conducted in the United States.

• Also, it hardly has any myelosuppression and has outstanding solubility to produce in injections.

• The candidate substance was approved by the KFDA for clinical study phase 1 last month and the study will begin in Seoul Asan Hospital next January.

   

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).